我们的研究目的是通过基于剂量的方法对患者对甲状腺功能亢进进行甲状腺功能亢进治疗的患者的患者相关的变量。
Four hundred twenty-four patients with hyperthyroidism related to Toxic Multinodular Goiter (TMG; n = 213), Grave’s disease (GD; n = 150) and toxic adenoma (TA; n = 61) treated with RAI between 2000 and 2018 and with at least 12 months follow-up were retrospectively evaluated. Association between outcomes (response vs. no response) at 6 and 12 months and baseline TSH values, anti-thyroid drugs (ATD) duration and posology, RAI absorbed dose and dimensional reduction of target mass at ultrasound was evaluated by Mann-Whitney test. Risk factors for response vs. no-response were analysed by binary logistic regression model.
整体反应率分别为78.7%和83%,分别为6和12个月。在6和12个月内,TSH基线值(P <0.001),较低的ATD持续时间(P = 0.004和P = 0.043),降低ATD病毒学(P = 0.014和P = 0.005),并将剂量降低到靶(D)(327 vs.373 GY,P = 0.003)与反应相关。较长的ATD持续时间和更高的ATD病毒学是在GD和TMG的6和12个月内无响应的独立风险因素,在TA子组中没有响应。
低TSH水平,较长的持续时间和较高的ATD病毒学与对RAI的更糟糕的反应相关。这些数据确认应在患者管理方面考虑RAI治疗,以允许更好的结果,避免毒性。

参考

PubMed.